The BioWorld Drug Developers Index (BDDI) continued its downward spiral through the fall, going from a modest 1.11% decline at the end of August to a 6.2% dip in September and an 11.3% loss by October’s close.
Researchers from Xencor Inc. presented the discovery and preclinical characterization of XmAb-942, a novel high-affinity anti-TL1A monoclonal antibody (MAb) being developed for the treatment of inflammatory bowel disease (IBD).
Atreca Inc. and Xencor Inc. have mutually selected the first program from their strategic collaboration combining an Atreca-discovered antibody with Xencor's Xmab bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).
Zenas Biopharma LLC in-licensed the global right to develop, manufacture, and commercialize the antibody obexelimab from Xencor Inc. to treat autoimmune diseases in a deal worth up to $480 million. Under the agreement, Monrovia, Calif.-based Xencor gained the rights to acquire additional shares in U.S. and China-based Zenas, which will bring its total equity up to 15%.
Xencor Inc. and Janssen Biotech Inc., already partners on the development of bispecific antibodies against CD28 for prostate cancer, have reached a second agreement licensing to Janssen exclusive development and commercialization rights to Xencor's phase I bispecific antibody, plamotamab, for the treatment of B-cell malignancies, both as a monotherapy and in combination regimens.
Zenas Biopharma LLC launched on March 23 as a U.S. funded cross-border biotech company targeting autoimmune diseases in China. The company, headquartered in Miromar Lakes, Fla., is founded and funded by Tellus Bioventures LLC and Fairmount Funds Management LLC.
Zenas Biopharma LLC launched on March 23 as a U.S. funded cross-border biotech company targeting autoimmune diseases in China. The company, headquartered in Miromar Lakes, Fla., is founded and funded by Tellus Bioventures LLC and Fairmount Funds Management LLC.
The always-busy American Society of Hematology meeting in December promises to include some especially intriguing datasets from the bispecific antibody space, as multiple players are likely to unveil findings related to their CD20xCD3 prospects.